Benjamin Christopher James

Benjamin Christopher James

Auto-generated profile, based on publicly available information

Benjamin Christopher James

Beth Israel Deaconess Medical Center

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 January 2023 in Frontiers in Endocrinology
Verified
Journal Article
Open access
NUNishant Uppal
Nishant Uppal
RCReagan Collins
Reagan Collins
BJBenjamin James
Benjamin James
Thyroid nodules have garnered attention due to changes in population surveillance systems and rising concerns about the associated financial burden on healthcare systems, payers, and patients. In this review, we find that prevalence rates vary widely based on method of detection and may particularly pronounced in asymptomatic patients undergoing routine screening. Incidence rates may be particularly rising in lower-income and middle-income countries and may be declining in higher-income countries. Despite high incidence rates, survival rates continue to be as high as 97% for papillary thyroid cancer. Over the last few decades, thyroid nodule workup and management has grown more sophisticated with the advent of fine-needle aspiration biopsy, specialized biomarkers, and molecular testing. However, gaps remain in risk stratification that can lead to substantial costs of care. Certain molecular tests, such as the Afirma Gene Sequencing Classifier can lead to a cost per diagnosis of $17,873 while achieving only mild decreases in diagnostic lobectomies for patients (11.6% to 9.7% in one study). Out-of-pocket costs associated with thyroid nodule management continue to drive significant financial toxicity for patients, especially for individuals with thyroid cancer. Financial toxicity has been defined as a term that describes how direct and indirect medical costs of cancer care strain patients and households via decreased income, assets, and spending on basic necessities. Recent studies suggest that such toxicity can lead to adverse financial outcomes, such as foreclosure and bankruptcy. Additional cost-effectiveness analyses are needed to improve existing thyroid nodule management systems and new clinical tools are needed to avoid unnecessary workup and management.

5 April 2018 in Cancer Causes & Control
Verified
Journal Article
Closed access
PDF file
BJBenjamin C. James
Benjamin C. James
JMJaneil M. Mitchell
Janeil M. Mitchell
HJHeedo D. Jeon
Heedo D. Jeon
NVNektarios Vasilottos
Nektarios Vasilottos
RGRaymon H. Grogan
Raymon H. Grogan
BABriseis Aschebrook-KIlfoy
Briseis Aschebrook-KIlfoy

1 February 2020 in Surgery
Verified
Journal Article
Closed access
CBCourtney E. Barrows
Courtney E. Barrows
JBJaneil M. Belle
Janeil M. Belle
AFAaron Fleishman
Aaron Fleishman
CLCarrie C. Lubitz
Carrie C. Lubitz
BJBenjamin C. James
Benjamin C. James

16 October 2020 in Thyroid®
Verified
Journal Article
Closed access
EREve M. Roth
Eve M. Roth
CLCarrie C. Lubitz
Carrie C. Lubitz
JSJohn Shannon Swan
John Shannon Swan
BJBenjamin Christopher James
Benjamin Christopher James
Background: There is an escalating worldwide population of thyroid cancer (TC) survivors. In addition to conventional metrics of quality of care, quality-of-life (QoL) assessment in TC patients is imperative. TC survivors face unique impediments to health-related quality of life (HRQoL), including thyroid-specific symptoms and exposure to disease-related stressors—including fear of recurrence and financial toxicity—over a prolonged survival period. Survey instruments currently used to assess HRQoL in TC survivors may be insufficient to accurately capture the burden of disease in this population. We aimed to identify the HRQoL instruments in the literature, which have been applied in the TC survivor population, and to present the psychometric properties of the scales and indexes that have been used. We hypothesized that few instruments have shown evidence of validity in this population. Summary: Of the 927 articles identified by search criteria, only 28 studies using 15 HRQoL instruments met inclusion criteria. Of the 15 HRQoL instruments identified, 9 were psychometric health status instruments and 6 were preference-based indexes, but none had been validated in the TC survivor population. While the majority of reviewed studies demonstrated impaired psychological and emotional well-being in TC survivors, these findings were not uniformly demonstrated across studies, and the longevity of the impact of TC on HRQoL was variably reported. Conclusions: Discrepancies in the literature regarding the impact of TC survivorship on HRQoL emphasize the challenges of accurately assessing patient perspectives, reinforcing the importance of using well-constructed instruments to measure patient-reported outcomes in the target population. Care providers involved in the treatment of TC survivors should be aware of longitudinal effects on HRQoL, especially pertaining to chronic psychological debilitation. Further development and rigorous validation of TC-specific instruments will allow for better data gathering and understanding of the barriers to achieving high long-term HRQoL in TC survivors throughout their long postsurvival course.

1 July 2019 in Surgery
Verified
Journal Article
Closed access
BJBenjamin C. James
Benjamin C. James
LTLava Timsina
Lava Timsina
RGRyan Graham
Ryan Graham
PAPeter Angelos
Peter Angelos
DHDavid A. Haggstrom
David A. Haggstrom

25 March 2021 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
SFScott C. Fligor
Scott C. Fligor
BLBetzamel Lopez
Betzamel Lopez
NUNishant Uppal
Nishant Uppal
CLCarrie C. Lubitz
Carrie C. Lubitz
BJBenjamin C. James
Benjamin C. James